NCT05370807 2023-10-24
RegoMel
Universitair Ziekenhuis Brussel
Phase 2 Unknown
Clinical Trials
4 trialsNCT02307500 2022-09-10
RESOUND
Istituto Clinico Humanitas
Phase 2 Completed
NCT02501551 2021-04-05
Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy
Yonsei University
Phase 2 Unknown
NCT02587650 2020-01-27
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
University of California, San Francisco
Phase 2 Terminated